Company intelligence / Profile preview

Vaxart, Inc.

South San Francisco, California, United Statesvaxart.com ↗

Ownership: Public · VXRT
Employees: ~109
Development stage: Phase 2

Overview

Vaxart has completed Phase 1 trials for its oral COVID‑19 vaccine candidate and advanced to Phase 2 studies. Its norovirus and seasonal influenza tablet vaccines are also in or approaching Phase 2. The company’s HPV therapeutic vaccine program represents its first immuno-oncology indication. No products have reached commercialization yet; all programs remain in clinical development.

Therapeutic areas: Infectious Diseases
Modalities: Oral recombinant vaccines (tablet form)Adenovirus vector-based vaccines
Industry: Biotech

Drug pipeline

45 assets

VXA-A1.1

Approved

44 more assets in the full pipeline.

Request access →

Financials

Market cap: $152.4M
Total revenue: $39.2M
Enterprise value: $99.4M

Beyond the preview

Go deeper on Vaxart, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vaxart, Inc..

Explore the full profile